Hyderabad-based drugmaker Aurobindo Pharma on Monday said that their anti-diabetic drug Metformin Hydrochloride extended release tablets USP got final approval from United States Food and Drug Administration (USFDA). The company said it was all set to launch the drug in US market soon.
Metformin Hydrochloride is a generic version of Bristol Myers Squibb’s Glucophage XR brand that is used to improve glycemic control in patients suffering from type-2 diabetes and has annual sales of around US$230 million.
The company said the product had been approved for sales in the US market out of its Unit III formulations facility in Hyderabad, which till recently was under an import ban by USFDA.
The tablets are indicated to control glucose levels in patients with type II diabetes.
The company also said that the product will be made in Hyderabad and exported to the US. The company’s Hyderabad plant had been slapped with an import ban by USFDA last year after an inspection revealed that the plant’s facilities weren’t up to the mark but the ban has been lifted now.
Following USFDA’s inspection of the unit in March this year, the company has recently started getting the US drug regulator’s approvals for drugs like blood thinner clopidogrel and psychiatric drug Quetiapine. Currently, Aurobindo’s other banned unit VI, which makes cephalosporin based drugs, is awaiting the clearance from USFDA.....
- Arts & Entertainment
- Computer & Internet
- News & Media
- Science & Technology
Who Voted for this Story
Friend Lane is started to create a website where you can find best and useful links at relevant catagory. We are working hard to manage it, submitters please be careful while submitting links or articles.